We enable nucleic acid labeling bioconjugation
Generic selectors
Exact matches only
Search in title
Search in content
product_variation

Science

Development of a XBP1 Sequencing Kit
MILESTONE
Background:
baseclick is developing a diagnostic research tool for breast cancer, glioblastoma and prostate cancer. A very good candidate is the transcription XBP1. Expression of mutated XBP1 has been implicated in cancer progression. Its functions as transcription factor and depletion of normal XBP1 as well as expression of mutated XBP1 in cancer cells leads to cell division. Mutated XBP1 is produced in stressed cells and cancer situation when the IRE1 switches from its normal chaperon function in the ER to RNase function and unnatural cytoplasmic splicing of XBP1 mRNA occurs (XBP1s/XBP1u) leading to two forms of XBP1 protein in cancer cells. Triple-negative breast cancer (TNBC) lacks targeted therapies and has a worse prognosis than other breast cancer subtypes, underscoring an urgent need for new therapeutic targets and strategies. Our goal is to identify the best treatment for every single patient (enables personalized medicine) and monitor the treatment via transcriptome analysis.
Cooperation partner:
National University of Ireland, Galway
IRE1/XBP1 drug development
MILESTONE
Background:
The trans autophosphorylation of the kinase domain of IRE1 activates its unusual effector function, which causes the unconventional splicing of the mRNA that encodes a transcription factor XBP1. Abnormalities in XBP1 lead to ER stress and subsequently causes susceptibility for inflammatory processes that contribute to cancer. baseclick started a program whereby oligonucleotides are tested to inhibit RNase activity of IRE1 for anticancer therapy.
Cooperation partner:
National University of Ireland, Galway
Inhibition of SARS-CoV-2 replication
MILESTONE
Backgorund:
Development of RNA / DNA gene scissors for specific cleavage of viral SARS-CoV-2 genomes to inhibit viral replication. The overall goal is to design a SARS-CoV-2 drug based on an artificial gene editing method. Therefore, an oligo linked with a metal complexes capable of cutting will direct the “gene scissor” to the SARS-CoV-2 RNA in infected cells leading to inhibition of viral replication.
Cooperation partner:
Dublin City University, Ireland
Invention of a new microRNA NGS method
MILESTONE
Background:
baseclick has begun a collaboration aimed at a fundamental understanding of the genetic and epigenetic mechanisms by which ribonucleic acids (RNAs) influence gene expression, development, epigenetic inheritance and evolution. The focus is on the regulation of epigenetic information by small RNAs (sRNAs). Our technology and experience in Next Generation Sequencing (NGS) opens up new dimensions in this research area. A collaboration was started to study small RNAs in order to understand the mechanisms of cellular and systemic gene regulation and virus defense.
Cooperation partner:
Bergische Universität Wuppertal, Germany
Targeting agents und cellular uptake
MILESTONE
Background:
Since 2014 baseclick is interested to utilizing click chemistry approaches to modify and conjugate targeting chemical entities to nucleic acids for tissue and cellular targeting and has filed several patents in this field even producing oligomeric modified nucleic acids for customer. One focus is directed to sugar conjugated nucleic acids, in particular RNA species such as siRNA, LNA or mRNA. These RNAs are conjugated to sugars such as glucose, mannose, GalNac and others for tissue and cellular targeting. In cooperation with various partners different sugar receptors are investigated. The modified nucleic acids are developed for targeted drug delivery strategies to treat infectious diseases, cancer and others.
Cooperation partner:
University of Groningen, Netherlands